Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

β-catenin expression in benign and malignant pleural disorders.

Anani W, Bruggeman R, Zander DS.

Int J Clin Exp Pathol. 2011;4(8):742-7. Epub 2011 Oct 30.

2.

Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.

Shi M, Fraire AE, Chu P, Cornejo K, Woda BA, Dresser K, Rock KL, Jiang Z.

Am J Surg Pathol. 2011 Jun;35(6):878-82. doi: 10.1097/PAS.0b013e318218985b.

PMID:
21566519
5.

How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.

Husain AN, Mirza MK, Gibbs A, Hiroshima K, Chi Y, Boumendjel R, Stang N, Krausz T, Galateau-Salle F.

Lung Cancer. 2014 Mar;83(3):324-8. doi: 10.1016/j.lungcan.2013.12.009. Epub 2013 Dec 30.

PMID:
24440278
6.

The separation of benign and malignant mesothelial proliferations.

Churg A, Colby TV, Cagle P, Corson J, Gibbs AR, Gilks B, Grimes M, Hammar S, Roggli V, Travis WD.

Am J Surg Pathol. 2000 Sep;24(9):1183-200. Review.

PMID:
10976692
7.
8.

Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?

Deniz H, Kibar Y, Güldür ME, Bakir K.

Pathol Res Pract. 2009;205(11):749-52. doi: 10.1016/j.prp.2009.06.001. Epub 2009 Jul 1.

PMID:
19573998
9.

Cadherins, catenins and APC in pleural malignant mesothelioma.

Abutaily AS, Collins JE, Roche WR.

J Pathol. 2003 Nov;201(3):355-62.

PMID:
14595746
10.

Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach.

Kradin RL, Mark EJ.

Semin Diagn Pathol. 2006 Feb;23(1):4-14. Review.

PMID:
17044190
11.

Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.

Üçer Ö, Dağli AF, Kiliçarslan A, Artaş G.

Turk Patoloji Derg. 2013;29(2):94-100. doi: 10.5146/tjpath.2013.01158.

12.

[Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].

Liu Y, Chen X, Ding N, Xu W, Yang H, Chen X.

Zhonghua Bing Li Xue Za Zhi. 2015 Apr;44(4):262-5. Chinese.

PMID:
25975910
13.

Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.

Sington JD, Morris LS, Nicholson AG, Coleman N.

Histopathology. 2003 May;42(5):498-502.

PMID:
12713628
15.
16.

[Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].

Krismann M, Thattamparambil P, Simon F, Johnen G.

Pathologe. 2006 Mar;27(2):99-105. German.

PMID:
16435096
17.
18.

Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma.

Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y.

Mod Pathol. 2007 Feb;20(2):215-20. Epub 2006 Dec 22.

19.

Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.

Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S.

Mod Pathol. 2008 Jun;21(6):742-7. doi: 10.1038/modpathol.2008.45. Epub 2008 Mar 7.

20.

My approach to the diagnosis of mesothelial lesions.

Butnor KJ.

J Clin Pathol. 2006 Jun;59(6):564-74.

Supplemental Content

Support Center